However, the primary research paper often cited by that community regarding the drug's potential anti-cancer mechanisms is:
Source: Nature Scientific Reports / PubMed Central Date: August 9, 2018 Key Findings: Fenbendazole.org intersect.rar
A report detailing three cases of advanced cancer (breast, prostate, and melanoma) where patients achieved remission after adding Fenbendazole to their regimens. Fenbendazole as an Anticancer Agent? A Case Series . However, the primary research paper often cited by
It promotes the activation of the p53 tumor suppressor protein, leading to programmed cell death (apoptosis). Other Notable Papers It promotes the activation of the p53 tumor
The American Cancer Society and other health authorities emphasize that while laboratory studies exist, Fenbendazole is not FDA-approved for human use, and large-scale clinical trials are still needed to confirm its safety and efficacy in people.
The drug interferes with tubulin polymerization, a process essential for cancer cell division.
Research indicating that the drug may target cancer stem cells, which are often resistant to standard treatments. Fenbendazole Exhibits Antitumor Activity Against Cervical Cancer .